Flag of the European Union EU Clinical Trials Register Help

Clinical trials

The European Union Clinical Trials Register allows you to search for protocol and results information on:
  • interventional clinical trials that are conducted in the European Union (EU) and the European Economic Area (EEA);
  • clinical trials conducted outside the EU / EEA that are linked to European paediatric-medicine development.
  • Learn   more about the EU Clinical Trials Register   including the source of the information and the legal basis.


    The EU Clinical Trials Register currently displays   38003   clinical trials with a EudraCT protocol, of which   6235   are clinical trials conducted with subjects less than 18 years old.
    The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     

    < Back to search results

    Print Download

    Summary
    EudraCT Number:2018-001467-23
    Sponsor's Protocol Code Number:RC31/17/0450
    National Competent Authority:France - ANSM
    Clinical Trial Type:EEA CTA
    Trial Status:Ongoing
    Date on which this record was first entered in the EudraCT database:2019-02-25
    Trial results
    Index
    A. PROTOCOL INFORMATION
    B. SPONSOR INFORMATION
    C. APPLICANT IDENTIFICATION
    D. IMP IDENTIFICATION
    D.8 INFORMATION ON PLACEBO
    E. GENERAL INFORMATION ON THE TRIAL
    F. POPULATION OF TRIAL SUBJECTS
    G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL
    N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED
    P. END OF TRIAL
    Expand All   Collapse All
    A. Protocol Information
    A.1Member State ConcernedFrance - ANSM
    A.2EudraCT number2018-001467-23
    A.3Full title of the trial
    Dexamethasone plus salvage chemotherapy versus salvage chemotherapy alone in patients with first relapsed or refractory acute myeloid leukemia: a randomized, controlled, open-label, multicenter, phase III study.
    Essai de phase III multicentrique, contrôlé, randomisé, en ouvert, évaluant l’efficacité de l’addition de la dexamethasone à la chimiothérapie de rattrapage versus la chimiothérapie de rattrapage seule chez les patients atteints de Leucémie Aiguë Myéloïde réfractaire ou en rechute
    A.3.1Title of the trial for lay people, in easily understood, i.e. non-technical, language
    Dexamethasone in first relapsed or refractory acute myeloid leukemia
    Dexaméthasone chez les patients atteints de Leucémie Aiguë Myéloïde réfractaire ou en rechute
    A.3.2Name or abbreviated title of the trial where available
    DEXAML-03
    DEXAML-03
    A.4.1Sponsor's protocol code numberRC31/17/0450
    A.5.2US NCT (ClinicalTrials.gov registry) numberNCT03765541
    A.7Trial is part of a Paediatric Investigation Plan No
    A.8EMA Decision number of Paediatric Investigation Plan
    B. Sponsor Information
    B.Sponsor: 1
    B.1.1Name of SponsorCHU de Toulouse
    B.1.3.4CountryFrance
    B.3.1 and B.3.2Status of the sponsorNon-Commercial
    B.4 Source(s) of Monetary or Material Support for the clinical trial:
    B.4.1Name of organisation providing supportCelgene
    B.4.2CountrySwitzerland
    B.4.1Name of organisation providing supportJanssen Pharmaceutica NV
    B.4.2CountryBelgium
    B.4.1Name of organisation providing supportMillenium Pharmaceuticals
    B.4.2CountryUnited States
    B.5 Contact point designated by the sponsor for further information on the trial
    B.5.1Name of organisationCHU de Toulouse
    B.5.2Functional name of contact pointBOGDANOVITCH
    B.5.3 Address:
    B.5.3.1Street Address2 rue viguerie
    B.5.3.2Town/ cityToulouse
    B.5.3.3Post code31059
    B.5.3.4CountryFrance
    B.5.4Telephone number330561778437
    B.5.5Fax number330561778411
    B.5.6E-mailbogdanovitch.l@chu-toulouse.fr
    D. IMP Identification
    D.IMP: 1
    D.1.2 and D.1.3IMP RoleTest
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation No
    D.2.1.1.1Trade name DEXAMETHASONE MYLAN
    D.2.1.1.2Name of the Marketing Authorisation holderMYLAN
    D.2.1.2Country which granted the Marketing AuthorisationFrance
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
    D.2.5.1Orphan drug designation number
    D.3 Description of the IMP
    D.3.1Product nameDEXAMETHASONE
    D.3.4Pharmaceutical form Solution for injection
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPIntravenous use
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin Yes
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) No
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D.3.11.3.1Somatic cell therapy medicinal product No
    D.3.11.3.2Gene therapy medical product No
    D.3.11.3.3Tissue Engineered Product No
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) No
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product No
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product No
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.8 Information on Placebo
    E. General Information on the Trial
    E.1 Medical condition or disease under investigation
    E.1.1Medical condition(s) being investigated
    Relapse or refractory Acute Myeloid Leukemia
    Leucémie Aiguë Myéloïde réfractaire ou en rechute
    E.1.1.1Medical condition in easily understood language
    Acute Myeloid Leukemia
    Leucémie Aiguë Myéloïde
    E.1.1.2Therapeutic area Diseases [C] - Cancer [C04]
    MedDRA Classification
    E.1.2 Medical condition or disease under investigation
    E.1.2Version 20.0
    E.1.2Level LLT
    E.1.2Classification code 10000886
    E.1.2Term Acute myeloid leukemia
    E.1.2System Organ Class 100000004864
    E.1.2 Medical condition or disease under investigation
    E.1.2Version 20.0
    E.1.2Level LLT
    E.1.2Classification code 10060558
    E.1.2Term Acute myeloid leukemia recurrent
    E.1.2System Organ Class 100000004864
    E.1.2 Medical condition or disease under investigation
    E.1.2Version 20.0
    E.1.2Level LLT
    E.1.2Classification code 10000889
    E.1.2Term Acute myeloid leukemia without mention of remission
    E.1.2System Organ Class 100000004864
    E.1.3Condition being studied is a rare disease Yes
    E.2 Objective of the trial
    E.2.1Main objective of the trial
    To evaluate if Dexamethasone plus salvage chemotherapy versus salvage chemotharapy alone provide significant improvement of overall survival in patient with first relapse or refractory acute myeloid leukemia
    Evaluer si l’ajout de la Dexaméthasone au traitement standard de rattrapage améliore de façon significative le temps de survie chez les patients de 18 ans ou plus atteints de LAM réfractaire ou en rechute après chimiothérapie intensive.
    E.2.2Secondary objectives of the trial
    - to evaluate the response to therapy
    - to evaluate the minimal residual disease (MRD) positivity
    - to evaluate the allogeneic hematopoietic stem cell transplantation as alternative therapy
    - to evaluate the time of remission
    - to evaluate the relapse-free survival
    - to evaluate quality of life
    - to evaluate adverse events
    - évaluer la réponse à la thérapie
    - évaluer le taux de maladie résiduelle
    - évaluer la transplantation de cellules souches hématopoïétiques allogéniques comme thérapie alternative
    - évaluer la durée de la rémission
    - évaluer le aux de survie sans progression
    - évaluer la qualité de vie des patients
    - évaluer les effets secondaires
    E.2.3Trial contains a sub-study No
    E.3Principal inclusion criteria
    - 18 years of age or older
    - Diagnosis of acute myeloid leukemia (AML) by World Health Organization (WHO) classification. First relapsed or refractory AML with at least 5% blasts by bone marrow biopsy or aspirate, or at least 1% blasts in peripheral blood, and meeting the following criteria :
    First relapsed AML:
    * First relapse occurred at least 90 days to 24 months after the first CR or CRi.
    * The first CR or CRi had to result from no more than 2 cycles of cytotoxic chemotherapy. At least 1 induction cycle must have consisted of an anthracycline and cytarabine combination with a reasonable schedule/dose of anthracycline in the judgment of the investigator.
    * The re-emergence of at least 5% leukemic blasts in bone marrow is not attributable to other causes, regardless of new or recurrent dysplastic changes or extramedullary disease, or the re-emergence of at least 1% blasts in the peripheral blood is not attributable to other causes such as regenerating marrow.
    Refractory AML:
    * Persistent AML was documented by bone marrow biopsy or aspirate at least 28 days after day 1 of the first induction cycle of 1 or 2 cycles of cytotoxic chemotherapy.
    * Re-emergence of at least 5% leukemic blasts in bone marrow or at least 1% blasts in peripheral blood is not attributable to other causes such as regenerating marrow, and was less than 90 days after the first CR or CRi.
    * Prior induction therapy had to include no more than 2 cycles of cytotoxic chemotherapy. At least 1 induction cycle must have consisted of an anthracycline and cytarabine combination with a reasonable schedule/dose of anthracycline in the judgment of the investigator.
    - Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2
    - Left ventricular ejection fraction (LVEF) ≥ 50% by echocardiogram or multi-gated acquisition (MUGA) scan; only applicable for patients who will receive intensive chemotherapy
    - Serum creatinine ≤ 150 µmol/L and/or total bilirubin ≤ 1.5 × the upper limit of normal (ULN) and/or, aspartate aminotransferase (AST) ≤ 2.5 × ULN and/or alanine aminotransferase (ALT) ≤ 2.5 × ULN (unless related to AML or due to Gilbert’s syndrome)
    - Any clinically significant non-hematological toxicity after prior chemotherapy must be resolved or of grade 1 as per Common Terminology Criteria for Adverse Events (CTCAE) version 4.03
    - Women must be surgically or biologically sterile, or in post-menopause (amenorrheic for at least 12 months), or if of childbearing potential, must have a negative urine or serum pregnancy test within 14 days prior to the randomization, and agree to use a highly effective method of contraception throughout the entire duration of the study treatment (including dose interruptions) and until 3 months after the last study treatment administration. Men must be surgically or biologically sterile, or agree to use a highly effective method of contraception throughout the entire duration of the study treatment (including dose interruptions) and until 6 months after the last study treatment administration
    - Registered to, or beneficiary of, social security insurance or equivalent
    - Signed written informed consent by both the patient and the investigator prior to perform any study-relayed procedure not part of normal medical care

    - Age ≥ 18 ans
    - Leucémie Aiguë Myéloïde (LAM) diagnostiquée selon la classification du WHO. LAM en première rechute ou réfractaire avec réémergence d'au moins 5% de blastes leucémiques documentée par aspiration de la moelle osseuse, et d'au moins 1% de blastes dans le sang périphérique et présentant les critères suivants :
    LAM en première rechute :
    * Première rechute survenant au moins 90 jours à 24 mois après la première RC ou RCi
    * La chimiothérapie d'induction qui ne devait pas inclure plus de 2 cycles de chimiothérapie cytotoxique et qui devait avoir comporté au moins un cycle combinant une anthracycline avec de la cytarabine
    * La réémergence d'au moins 5% de blastes leucémiques dans la moelle osseuse et ou d'au moins 1% de blastes dans le sang périphérique ne doit pas être attribuable à d'autres causes (régénération médullaire)
    LAM réfractaire :
    * LAM persistante documentée par aspiration de moelle osseuse au moins 28 jours après le jour 1 du 1er ou 2nd cycle de chimiothérapie d’induction
    * Réémergence d'au moins 5% de blastes leucémiques dans la moelle osseuse ou d'au moins 1% de blastes dans le sang périphérique non attribuable à d'autres causes (régénération médullaire) dans un délai inférieur à 90 jours après la première RC ou RCi
    * La première thérapie d'induction ne doit inclure pas plus de 2 cycles de chimiothérapie cytotoxique dont un cycle ayant comporté au moins un cycle combinant une anthracycline avec de la cytarabine
    - Indice de performance ECOG ≤ 2
    - Fraction d'éjection du ventricule gauche (FEVG) d'au moins 50% par échographie ou scintigraphie ; critère applicable uniquement aux patients qui recevront la chimiothérapie intensive amsacrine-cytarabine en traitement standard de rattrapage
    - Créatinine sérique ≤ 150 ╬╝mol/L ou bilirubine totale ≤ 1,5 X la limite supérieure de la normale (LSN) ou aspartate amino-transférase (AST) ≤ 2,5 X LSN ou alanine amino-transférase (ALT) ≤ 2,5 X LSN (à moins d'être considérée comme due à une atteinte leucémique ou à une maladie de Gilbert)
    - Toute toxicité non hématologique cliniquement significative après une chimiothérapie antérieure doit être résolue ou de grade 1 selon les critères communs de terminologie pour les événements indésirables (CTCAE) version 4.03
    - Les femmes doivent être chirurgicalement ou biologiquement stériles ou en post-ménopause (aménorrhées pendant au moins 12 mois). Les femmes en âge de procréer doivent avoir un test de grossesse négatif dans les 14 jours précédant la randomisation et accepter d'utiliser une méthode de contraception adéquate pendant toute la durée de traitement et jusqu’à 3 mois après le dernier traitement. Les hommes doivent être chirurgicalement ou biologiquement stériles ou accepter d'utiliser une méthode de contraception adéquate pendant toute la durée de traitement et jusqu'à 6 mois après le dernier traitement
    - Patients affiliés ou bénéficiaires d’un régime de sécurité sociale (Sécurité Sociale ou Couverture Médicale Universelle)
    - Consentement libre, éclairé et écrit, signé par le patient et l’investigateur (avant tout examen nécessité par la recherche)
    E.4Principal exclusion criteria
    - Acute promyelocytic leukemia (M3 subtype of AML)
    - More than 2 cycles of first line induction chemotherapy
    - AML with Philadelphia chromosome or BCR-ABL1 or blast crisis stage of chronic myeloid leukemia
    - Known or suspected central nervous system leukemia
    - Undergoing allogeneic hematopoietic stem cell transplantation within 90 days prior to randomization, or being on immunosuppressive therapy for prophylaxis of graft-versus-host disease (GVHD), or experiencing GVHD within 2 weeks prior to randomization
    - Use of any experimental, cytotoxic, or targeted, anti-leukemic therapy within 14 days prior to randomization, with the exception of hydroxyurea
    - Formal contraindication to glucocorticoids
    - Non-AML-associated organic or psychiatric severe disease that contraindicates use of study treatment
    - Patients who may not be followed regularly in consultation because of psychological, family, social, or geographical reasons
    - History of uncontrolled other malignancy for at least two years, with the exception of basal cell carcinoma and in situ cervix carcinoma
    - Severe uncontrolled infection at time of inclusion
    - Positive serology for HIV-1 or 2, and/or HTLV-1 or 2, and/or active viral infection with hepatitis B virus (HBV) and/or hepatitis C virus (HCV)
    - Pregnant (beta HCG positive) or breastfeeding woman
    - Incapable patient of age, under guardianship, curatorship or safeguard of justice
    - Patient Under State Medical Assistance
    - Patient participating in any other interventional clinical trial or having participated in an interventional clinical trial of which the exclusion period is still ongoing.
    - Leucémie aigüe promyélocytaire (soustype M3 de LAM)
    - Plus de 2 cycles de chimiothérapie d’induction reçus en première ligne
    - LAM avec chromosome Philadelphie ou réarrangement BCR-ABL1 ou crise blastique d’une leucémie myéloïde chronique
    - Atteinte leucémique du système nerveux central connue ou suspectée
    - Allogreffe de cellules souches hématopoïétiques dans les 90 jours avant la randomisation ou traitement immunosuppresseur pour la prophylaxie de la maladie greffon contre l'hôte (GVHD) ou GVHD dans les 2 semaines avant la randomisation
    - Tout traitement anti-leucémique expérimental, cytotoxique ou ciblé dans les 14 jours précédant la randomisation à l’exception de l’hydroxyurée
    - Patients présentant une contre-indication formelle aux glucocorticoïdes
    - Patients atteints d'une pathologie organique ou psychiatrique sévère, présumée indépendante de la LAM et contre-indiquant le traitement
    - Patients qui, pour des raisons psychologiques, familiales, sociales ou géographiques, ne pourraient être suivis régulièrement en consultation
    - Antécédent de cancer non contrôlé depuis au moins deux ans à l’exception des carcinomes cutanés baso-cellulaires et des carcinomes in situ du col utérin
    - Infection sévère non contrôlée au moment de l'inclusion
    - Sérologie positive pour VIH-1 ou 2 ou HTLV-1 ou 2, ou infection virale active à VHB ou à VHC
    - Femme enceinte (bêta HCG positives) ou en cours d'allaitement
    - Patient incapable majeur, sous tutelle, curatelle ou sauvegarde de justice
    - Patient sous Aide Médicale d’Etat
    - Patient participant à un autre essai interventionnel ou ayant participé à un essai interventionnel dont la période d’exclusion est toujours en cours
    E.5 End points
    E.5.1Primary end point(s)
    Overall survival
    Survie globale
    E.5.1.1Timepoint(s) of evaluation of this end point
    from randomization up to the end of the study
    depuis la randomisation jusqu'à la fin de l'étude
    E.5.2Secondary end point(s)
    - response to therapy
    - minimal residual disease positivity
    - allogenein hematopoeitic stem cell transplantation therapy
    - duration of remission
    - relapse-free survival
    - event-free survival
    - quality of life
    - adverse events
    - réponse à la thérapie
    - taux de maladie résiduelle positive
    - transplantation de cellules souches hématopoïétiques allogéniques
    - durée de rémission
    - survie sans progression
    - survie sans événement
    - qualité de vie
    - événements indésirables
    E.5.2.1Timepoint(s) of evaluation of this end point
    from randomisation up to the end of the study for all secondary end points exepted for quality of life (at baseline, at evaluation of the complete remission, on Day 1 before dosing of each post-remission cycle, at end of the study treatment) and for adverse events (during the whole study period)
    depuis la randomisation jusqu'à la fin de l'étude pour tous les critères de jugement secondaires sauf pour la qualité de vie (avant tout traitement, lors de l'évaluation de la rémission complète, le premier jour après chaque cycle post-remission et à la fin du traitement) et pour les événements indésirables (durant toute la durée de l'étude)
    E.6 and E.7 Scope of the trial
    E.6Scope of the trial
    E.6.1Diagnosis No
    E.6.2Prophylaxis No
    E.6.3Therapy Yes
    E.6.4Safety Yes
    E.6.5Efficacy Yes
    E.6.6Pharmacokinetic No
    E.6.7Pharmacodynamic No
    E.6.8Bioequivalence No
    E.6.9Dose response No
    E.6.10Pharmacogenetic No
    E.6.11Pharmacogenomic No
    E.6.12Pharmacoeconomic No
    E.6.13Others No
    E.7Trial type and phase
    E.7.1Human pharmacology (Phase I) No
    E.7.1.1First administration to humans No
    E.7.1.2Bioequivalence study No
    E.7.1.3Other No
    E.7.1.3.1Other trial type description
    E.7.2Therapeutic exploratory (Phase II) No
    E.7.3Therapeutic confirmatory (Phase III) Yes
    E.7.4Therapeutic use (Phase IV) No
    E.8 Design of the trial
    E.8.1Controlled Yes
    E.8.1.1Randomised Yes
    E.8.1.2Open Yes
    E.8.1.3Single blind No
    E.8.1.4Double blind No
    E.8.1.5Parallel group No
    E.8.1.6Cross over No
    E.8.1.7Other No
    E.8.2 Comparator of controlled trial
    E.8.2.1Other medicinal product(s) Yes
    E.8.2.2Placebo No
    E.8.2.3Other No
    E.8.2.4Number of treatment arms in the trial2
    E.8.3 The trial involves single site in the Member State concerned No
    E.8.4 The trial involves multiple sites in the Member State concerned Yes
    E.8.4.1Number of sites anticipated in Member State concerned9
    E.8.5The trial involves multiple Member States No
    E.8.6 Trial involving sites outside the EEA
    E.8.6.1Trial being conducted both within and outside the EEA No
    E.8.6.2Trial being conducted completely outside of the EEA No
    E.8.7Trial has a data monitoring committee Yes
    E.8.8 Definition of the end of the trial and justification where it is not the last visit of the last subject undergoing the trial
    LVLP
    DVDP
    E.8.9 Initial estimate of the duration of the trial
    E.8.9.1In the Member State concerned years
    E.8.9.1In the Member State concerned months
    E.8.9.1In the Member State concerned days
    F. Population of Trial Subjects
    F.1 Age Range
    F.1.1Trial has subjects under 18 No
    F.1.1.1In Utero No
    F.1.1.2Preterm newborn infants (up to gestational age < 37 weeks) No
    F.1.1.3Newborns (0-27 days) No
    F.1.1.4Infants and toddlers (28 days-23 months) No
    F.1.1.5Children (2-11years) No
    F.1.1.6Adolescents (12-17 years) No
    F.1.2Adults (18-64 years) Yes
    F.1.2.1Number of subjects for this age range: 71
    F.1.3Elderly (>=65 years) Yes
    F.1.3.1Number of subjects for this age range: 71
    F.2 Gender
    F.2.1Female Yes
    F.2.2Male Yes
    F.3 Group of trial subjects
    F.3.1Healthy volunteers No
    F.3.2Patients Yes
    F.3.3Specific vulnerable populations No
    F.3.3.1Women of childbearing potential not using contraception No
    F.3.3.2Women of child-bearing potential using contraception No
    F.3.3.3Pregnant women No
    F.3.3.4Nursing women No
    F.3.3.5Emergency situation No
    F.3.3.6Subjects incapable of giving consent personally No
    F.3.3.7Others No
    F.4 Planned number of subjects to be included
    F.4.1In the member state142
    F.5 Plans for treatment or care after the subject has ended the participation in the trial (if it is different from the expected normal treatment of that condition)
    It is not different from expected in progressive disease. It will be decided as per usual center practice
    Il n'est pas différent de celui en cas de progression. Il sera décidé conformément à la pratique habituelle des centres
    G. Investigator Networks to be involved in the Trial
    N. Review by the Competent Authority or Ethics Committee in the country concerned
    N.Competent Authority Decision Authorised
    N.Date of Competent Authority Decision2019-04-19
    N.Ethics Committee Opinion of the trial applicationFavourable
    N.Ethics Committee Opinion: Reason(s) for unfavourable opinion
    N.Date of Ethics Committee Opinion2019-04-16
    P. End of Trial
    P.End of Trial StatusOngoing
    As of 1.2.2020, the UK is no longer an EU Member State. However, EU law still applies to the UK during the transition period
    EU Clinical Trials Register Service Desk: https://servicedesk.ema.europa.eu
    European Medicines Agency © 1995-2020 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    Legal notice
    EMA HMA